Topline results from a pooled clinical study show that Mainz Biomed’s portfolio of proprietary novel gene expression (mRNA) biomarkers can be used in a next generation version of the company’s colorectal cancer screening tool. The study included new patients and subjects from Mainz Biomed’s ColoFuture (Europe) and eAArly DETECT (U.S.) clinical trials. The topline results confirm the positive efficacy results previously reported with a sensitivity for colorectal cancer of 92% with a specificity of 90% and a sensitivity for advanced adenoma of 82%, the company said.
The United States has a translation problem. Scientific breakthroughs in oncology are accelerating, but clinical trial infrastructure hasn’t kept pace.
